For research use only
| Cat No. | ABC-TC1342 |
| Product Type | Human Lung Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Product Code | NCI-H460, H460 Cells, NCIH460, Human Non-Small Cell Lung Cancer Cell Line NCI-H460 |
NCI-H460 cells exhibit traits of epithelial-mesenchymal transition and aggressive growth, useful for lung cancer metastasis and drug resistance research.
NCI-H460 is a human non‑small cell lung cancer (NSCLC) cell line cells were isolated in 1982 from the pleural fluid of a male patient with large cell lung cancer. These adherent cells exhibit epithelial-like morphology, forming tightly packed monolayer colonies, and co‑express keratin and vimentin, indicative of both epithelial and mesenchymal phenotypes. These cells have a hypotriploid karyotype, with a modal chromosome number of 57 (range 53–65). NCI‑H460 frequently harbors activating mutations in KRAS and PIK3CA, with occasional TP53/RB1 alterations, mimicking key signaling deregulations in clinical NSCLC. NCI-H460 demonstrates tumorigenic potential in nude mice models, forming subcutaneous xenografts. This combination makes NCI‑H460 a versatile, translational model of aggressive lung carcinoma.
| Product Code | NCI-H460, H460 Cells, NCIH460, Human Non-Small Cell Lung Cancer Cell Line NCI-H460 |
| Species | Human |
| Cat.No | ABC-TC1342 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
NCI-H460 serves as an in vitro and in vivo model for studying large cell lung carcinoma and for anticancer drug screening. They are particularly beneficial in 3D cell culture systems, allowing researchers to study tumor growth and evaluate therapeutic responses. The co-expression of epithelial (keratin) and mesenchymal (vimentin) markers makes this cell line valuable for studies on epithelial-mesenchymal transition (EMT) and metastasis progression. Moreover, NCI-H460 contributes to the development of targeted therapies, offering a relevant platform for testing compounds that modulate lung cancer signaling pathways.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
